Fraty et al. concluded that MR-proADM serves as a prognostic biomarker for HF in people with T2DM; however, compared with NT-proBNP, it does not provide significant complementary information on the prediction of HF without T2DM (50). This evidence concerns the gene NPPB and type 2 diabetes mellitus.